About Us

About Us

Building Better Therapies for a Brighter Future

Our journey is defined by a relentless commitment to making these innovative therapies more accessible, reliable, and effective for patients around the world, starting with Southeast Asia. At Celler Therapeutics, we recognize that CGT represents the next frontier in medicine, with the potential to provide revolutionary solutions for conditions that were once considered incurable. Our team of visionary scientists, engineers, and healthcare professionals has embarked on a mission to provide equitable access to these valuable therapies for doctors and their patients.

Our Values

Pioneering Tomorrow's Therapies Today

Mission

Our mission is to enhance the accessibility, reliability, and efficacy of these CGTs for patients globally, beginning with Southeast Asia.

Vision

To be a transformative force in the treatment of diseases and premature ageing in the pursuit living longer, healthier lives.

Values

To heal with compassion and scientific innovation, always guided by honesty, transparency, and urgency.

Our Team

Key Management

Sasha Omar Firdaus

Chief Executive Officer & Co-Founder
Sasha brings over two decades of leadership in genomics, clinical pathology, immunotherapy, and AI data science. He has held C-level and board positions at both public and private companies, and currently serves on the boards of several innovative start-ups. Sasha’s extensive experience drives our mission to improve equitable access to cell and gene therapies for clinicians across Southeast Asia.

Karthik Chandran

Chief Revenue Office & Co-Founder

With over 15 years of experience in the biopharmaceutical industry, Karthik has led teams in designing, setting up, and operating multiple GMP laboratories for cell therapy production. His extensive experience in clinical and non-clinical product development, quality, regulations, and clinical trials, including Malaysia’s first CAR-T trial, drives our innovative and regulatory excellence.

Pratip Kumar

Chief Operating Officer & Co-Founder
With nearly two decades of expertise in project, IT, and risk management, our Co-Founder and Chief Operating Officer brings a wealth of experience to our CGT production. He overseas our in-house operations, whilst also ensuring operational excellence and efficiency for biopharmaceutical customers who rely on us for contract development and manufacturing.

Our Team

Key Management

Sasha Omar Firdaus

Chief Executive Officer & Co-Founder
Sasha brings over two decades of leadership in genomics, clinical pathology, immunotherapy, and AI data science. He has held C-level and board positions at both public and private companies, and currently serves on the boards of several innovative start-ups. Sasha’s extensive experience drives our mission to improve equitable access to cell and gene therapies for clinicians across Southeast Asia.

Karthik Chandran

Chief Revenue Office & Co-Founder
With over 15 years of experience in the biopharmaceutical industry, Karthik has led teams in designing, setting up, and operating multiple GMP laboratories for cell therapy production. His extensive experience in clinical and non-clinical product development, quality, regulations, and clinical trials, including Malaysia’s first CAR-T trial, drives our innovative and regulatory excellence.

Pratip Chandra

Chief Operating Officer & Co-Founder
With nearly two decades of expertise in project, IT, and risk management, our Co-Founder and Chief Operating Officer brings a wealth of experience to our CGT production. He overseas our in-house operations, whilst also ensuring operational excellence and efficiency for biopharmaceutical customers who rely on us for contract development and manufacturing.

Our Team

Technical Advisory Board

Dr Sergei Kulemzin

CGT and Viral Vector Production

Dr Darryl Ong

Drug Design & Development

Dr Jungnam Lee

Protein Disorders

Dr Sareh Kamran

Molecular Pharmacology

Assoc. Prof. Dato Dr Badrul Akmal Hisham

Orthopaedics

Dr Vickneswaran Virasamy

Obstetrics and Gynaecology

Dr Kesavan Markkandan

Genomics

Transforming Cells, Transforming Lives

Clinical Pipeline

Expanded Access Policy

researcher working in laboratory for medicals science research using scientific equipment technology

Celler Therapeutics is committed to developing safe and innovative cell and gene therapies to address unmet medical needs and improve patient outcomes. We recognize that there are circumstances where patients may seek access to investigational therapies outside of clinical trials, particularly when traditional treatment options have been exhausted or are unavailable. Our Expanded Access Policy (EAP) is designed to provide a pathway for patients with serious or life-threatening conditions to access investigational therapies when they meet certain criteria and in accordance with applicable regulatory requirements. EAPs are also known as Special Access Programs.

Get Started

Join us in Unravelling the Mysteries of Regenerative Medicine

Driven by the conviction that no challenge is insurmountable, we integrate innovation with compassion to shape the future of medicine by leveraging cell and gene therapies to significantly improve patient outcomes.

Driven by the conviction that no challenge is insurmountable, we integrate innovation with compassion to shape the future of medicine by leveraging cell and gene therapies to significantly improve patient outcomes.

Scroll to Top